Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lete-cel + Pembrolizumab in Synovial Sarcoma
NCT03697824Phase 2Withdrawn
- Sponsor
- GSK
- Start
- Feb 2019
- Primary completion
- Jul 2022
- Modality
- CAR-T Cells
01
Overview
Phase 2, open-label, single-arm trial of letetresgene autoleucel in synovial sarcoma (SS), sponsored by GSK. Primary endpoints: Number of subjects with treatment limiting toxicities (TLT) at 2 years, Number of subjects with AEs at 2 years and 1 more. Planned start Feb 2019; status: withdrawn.
02
Drugs
letetresgene autoleucel
03
Conditions
synovial sarcoma (SS)
Beyond the preview
Go deeper on NCT03697824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03697824.